BUFDX
Price
$31.62
Change
-$0.01 (-0.03%)
Updated
Sep 20 closing price
VSTSX
Price
$269.69
Change
-$0.67 (-0.25%)
Updated
Sep 20 closing price
Ad is loading...

BUFDX vs VSTSX

Header iconBUFDX vs VSTSX Comparison
Open Charts BUFDX vs VSTSXBanner chart's image
Buffalo Growth & Income
Price$31.62
Change-$0.01 (-0.03%)
VolumeN/A
CapitalizationN/A
Vanguard Total Stock Mkt Idx Instl Sel
Price$269.69
Change-$0.67 (-0.25%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
BUFDX vs VSTSX Comparison Chart
Loading...
VS
BUFDX vs. VSTSX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BUFDX is a StrongBuy and VSTSX is a Buy.

FUNDAMENTALS
Fundamentals
VSTSX has more cash in the bank: 1.72T vs. BUFDX (164M). VSTSX (1.36) and BUFDX (1.35) have matching dividends . BUFDX was incepted earlier than VSTSX: BUFDX (12 years) vs VSTSX (8 years). BUFDX (2.00) and VSTSX (2.00) have comparable annual turnover. BUFDX has a lower initial minimum investment than VSTSX: BUFDX (2500) vs VSTSX (5000000000). VSTSX annual gain was more profitable for investors over the last year : 31.59 vs. BUFDX (27.68). BUFDX (86.38) and VSTSX (85.77) have equivalent 5 years return.
BUFDXVSTSXBUFDX / VSTSX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years8 years-
Gain YTD17.02218.66891%
Front LoadN/AN/A-
Min. Initial Investment250050000000000%
Min. Initial Investment IRAN/AN/A-
Net Assets164M1.72T0%
Annual Yield % from dividends1.351.3699%
Returns for 1 year27.6831.5988%
Returns for 3 years31.8925.41126%
Returns for 5 years86.3885.77101%
Returns for 10 years159.42N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTCX0.39N/A
+1.08%
Carmell Corp
OUT18.250.18
+1.00%
OUTFRONT Media
HITI2.11-0.03
-1.40%
High Tide
AMCR10.90-0.21
-1.89%
Amcor plc
FDMT11.90-1.60
-11.85%
4D Molecular Therapeutics